After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

Novo Nordisk announced a licensing agreement worth more than $1 billion days after holding a capital-markets presentation. The deal involves a Swedish company whose stock price rose following the announcement. Novo Nordisk did not disclose additional details about the licensing agreement or the Swedish partner in the announcement.

Next story